| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1995PNAS...9212260P |
| P356 | DOI | 10.1073/PNAS.92.26.12260 |
| P932 | PMC publication ID | 40336 |
| P698 | PubMed publication ID | 8618881 |
| P5875 | ResearchGate publication ID | 14581440 |
| P50 | author | Rémi Quirion | Q3456064 |
| P2093 | author name string | Poirier J | |
| Gauthier S | |||
| Farlow M | |||
| Nalbantoglu J | |||
| Aubert I | |||
| Bertrand P | |||
| Hui S | |||
| Delisle MC | |||
| Lahiri D | |||
| Gilfix BM | |||
| P2860 | cites work | Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 |
| Apolipoprotein E genotype and Alzheimer's disease | Q28249303 | ||
| Evidence for a membrane defect in Alzheimer disease brain | Q28343061 | ||
| Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease | Q29614952 | ||
| Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat | Q33245492 | ||
| Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes | Q33360009 | ||
| Apolipoproteins in human cerebrospinal fluid | Q33976139 | ||
| Synthesis of acetylcholine from choline derived from phosphatidylcholine in a human neuronal cell line | Q34335793 | ||
| Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain | Q34714755 | ||
| Choline metabolism as a basis for the selective vulnerability of cholinergic neurons | Q35318283 | ||
| Lipoprotein receptors and cholesterol homeostasis | Q40134833 | ||
| Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease | Q40397850 | ||
| Annular and nonannular binding sites for cholesterol associated with the nicotinic acetylcholine receptor | Q42214371 | ||
| Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey | Q42464648 | ||
| Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease | Q42526718 | ||
| A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group | Q44110810 | ||
| The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease | Q46484800 | ||
| Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). | Q48164740 | ||
| Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats | Q48256982 | ||
| Hippocampal membrane alteration in Alzheimer's disease | Q48287854 | ||
| Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. | Q48533491 | ||
| Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning | Q48668350 | ||
| A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. | Q52026922 | ||
| Intracellular membranes are more fluid in platelets of Alzheimer's disease patients | Q52048876 | ||
| Lewy bodies and response to tacrine in Alzheimer's disease. | Q53204289 | ||
| APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. | Q53205800 | ||
| Family study of platelet membrane fluidity in Alzheimer's disease. | Q53306162 | ||
| Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. | Q53312352 | ||
| Tacrine for senile dementia of Alzheimer's or Lewy body type. | Q53314602 | ||
| Apolipoprotein E polymorphism and Alzheimer's disease. | Q53316388 | ||
| Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. | Q53321766 | ||
| Determination of alpha-tocopherol, free cholesterol, esterified cholesterols and triacylglycerols in human lipoproteins by high-performance liquid chromatography | Q68670479 | ||
| Platelet membrane properties in Alzheimer and multi-infarct dementias | Q68713768 | ||
| Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins | Q68921833 | ||
| Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease | Q69111199 | ||
| Tacrine slows the rate of ageing of sarin-inhibited acetylcholinesterase | Q69683824 | ||
| Decreased myelin lipids in Alzheimer's disease and vascular dementia | Q69800363 | ||
| A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele | Q72319861 | ||
| Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies | Q72903012 | ||
| A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES | Q76898743 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 12260-12264 | |
| P577 | publication date | 1995-12-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease | |
| P478 | volume | 92 |
| Q51766239 | 18F-XTRA PET for enhanced imaging of the extrathalamic α4β2 nicotinic acetylcholine receptor. |
| Q37290059 | A Triple Network Connectivity Study of Large-Scale Brain Systems in Cognitively Normal APOE4 Carriers |
| Q53323924 | A pilot experience in genetic counseling for Alzheimer's disease. Findings relevant to the potential use of APOE genotyping in cognitively impaired individuals. |
| Q36454644 | A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism |
| Q41331923 | A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease |
| Q48245913 | A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease |
| Q36610058 | APOE E4 Carriers show prospective memory enhancement under nicotine, and evidence for specialisation within medial BA10. |
| Q52003353 | APOE genotyping and response to drug treatment in Alzheimer's disease. |
| Q37044205 | APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease |
| Q30471824 | Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E |
| Q34024117 | Advances in pharmacogenetics and pharmacogenomics |
| Q36311673 | Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent |
| Q41335909 | Alterations in apolipoprotein E expression during aging and neurodegeneration |
| Q37034397 | Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision |
| Q34192420 | Alzheimer's disease: current and future therapeutic perspectives |
| Q34025936 | Alzheimer's disease: current knowledge, management and research |
| Q42457830 | ApoE epsilon4 genotype is accompanied by lower metabolic activity in nucleus basalis of Meynert neurons in Alzheimer patients and controls as indicated by the size of the Golgi apparatus |
| Q43990900 | ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model |
| Q30341746 | ApoE-dependent plasticity in Alzheimer's disease. |
| Q47999987 | ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum |
| Q41454720 | Apolipoprotein E and Alzheimer's disease: a review of recent studies |
| Q37060457 | Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. |
| Q37009967 | Apolipoprotein E and cholesterol in aging and disease in the brain |
| Q37821616 | Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. |
| Q37478496 | Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease. |
| Q35794576 | Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene |
| Q53380063 | Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. |
| Q40916503 | Apolipoprotein E genotype and gender influence response to tacrine therapy |
| Q34145767 | Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues |
| Q43719513 | Apolipoprotein E isoform-specific disruption of phosphoinositide hydrolysis: protection by estrogen and glutathione |
| Q42462689 | Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease |
| Q34093070 | Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses |
| Q33337322 | Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. |
| Q28265290 | Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease |
| Q34258228 | Applied neurogenomics |
| Q91746910 | Assessment of In Vitro Bioactivities of Polysaccharides Isolated from Hericium Novae-Zealandiae |
| Q43864519 | Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. |
| Q50553487 | Attentional performance, impulsivity, and related neurotransmitter systems in apoE2, apoE3, and apoE4 female transgenic mice. |
| Q73222827 | Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease |
| Q50800255 | BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. |
| Q90592712 | Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration |
| Q33930330 | Biogerontological research in Canada |
| Q33416543 | Biological changes associated with healthy versus pathological aging: a symposium review |
| Q47681446 | Blockade of cholinergic receptors in rat barrel cortex prevents long-term changes in the evoked potential during sensory preconditioning |
| Q35480015 | Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease |
| Q34997893 | Bridging genetics and genomics in neurology |
| Q36959844 | CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein ε4 and Cigarette Smoking |
| Q35082774 | CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease |
| Q34609133 | Candidate gene approach for pharmacogenetic studies |
| Q34459045 | Candidate gene case-control association studies: advantages and potential pitfalls |
| Q30040327 | Cannabis and Cannabis Extracts |
| Q34037204 | Causes of Alzheimer's disease |
| Q41417768 | Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system |
| Q50524332 | Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults. |
| Q42475548 | Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice |
| Q36475090 | Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story |
| Q33637687 | Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease |
| Q33714955 | Clinical rationale of genetic testing in dementia |
| Q36142255 | Clinical trials in mild cognitive impairment: lessons for the future |
| Q38397411 | Cognitive predictors of donepezil therapy response in Alzheimer disease |
| Q28659646 | Combining heterogenous data for prediction of disease related and pharmacogenes |
| Q34071528 | Common gene variants, mortality and extreme longevity in humans. |
| Q35066849 | Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. |
| Q51907699 | Decreased cerebral blood flow velocity in apolipoprotein E epsilon4 allele carriers with mild cognitive impairment. |
| Q79918340 | Development of a SNP genotyping panel for genetic monitoring of the laboratory mouse |
| Q34519657 | Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q33791482 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease |
| Q42540026 | Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. |
| Q36241900 | EVALUATION OF HOW CIGARETTE SMOKE IS A DIRECT RISK FACTOR FOR ALZHEIMER'S DISEASE. |
| Q64864149 | Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years |
| Q36745685 | Education, ethics and knowledge deficits in clinical pharmacogenetics. |
| Q37510386 | Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease |
| Q33931093 | Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife |
| Q51847733 | Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. |
| Q50862046 | Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. |
| Q64101524 | Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update |
| Q37160197 | Effect of smoking and time on cognitive function in the elderly without dementia |
| Q38860423 | Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis |
| Q51866289 | Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. |
| Q58793678 | Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer’s disease |
| Q33742199 | Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease |
| Q34489699 | Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease |
| Q43120876 | Epistasis between APOE and nicotinic receptor gene CHRNA4 in age related cognitive function and decline |
| Q42517451 | Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice |
| Q34743306 | Ethical perspectives on pharmacogenomic profiling in the drug development process |
| Q53222007 | Evaluation of selection criteria used in Alzheimer's disease clinical trials. |
| Q48172445 | Evidence for homeostatic adjustments of rat somatosensory cortical neurons to changes in extracellular acetylcholine concentrations produced by iontophoretic administration of acetylcholine and by systemic diisopropylfluorophosphate treatment |
| Q97420369 | Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy |
| Q34355252 | Gene identification in Alzheimer's disease |
| Q34134818 | Genetic susceptibility factors for Alzheimer's disease. |
| Q35336866 | Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene |
| Q36466472 | Genetics, transcriptomics, and proteomics of Alzheimer's disease |
| Q35852564 | Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics |
| Q53220135 | Getting the right drug into the right patient. |
| Q46890625 | Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. |
| Q32091544 | Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. |
| Q36629655 | Hippocampal infusions of apolipoprotein E peptides induce long-lasting cognitive impairment |
| Q62395629 | Hippocampal structure and the action of cholinomimetic drugs |
| Q44303602 | Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study |
| Q36043405 | How frequent is altered gene expression among susceptibility genes to human complex disorders? |
| Q57995824 | Human Apolipoprotein E concentration in response to diseases and therapeutic treatments |
| Q73424836 | Human Genome Project and pharmacogenomics--implications for pharmacy |
| Q21262020 | Hypometabolism as a therapeutic target in Alzheimer's disease |
| Q47588776 | Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes |
| Q40028157 | Impact of detergents on the activity of acetylcholinesterase and on the effectiveness of its inhibitors |
| Q53349686 | Impacts of PICALM and CLU variants associated with Alzheimer's disease on the functional connectivity of the hippocampus in healthy young adults. |
| Q35102211 | Implications of pharmacogenetics for individualizing drug treatment and for study design |
| Q40081341 | Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. |
| Q53219345 | In defense of genomics. |
| Q44736078 | Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study |
| Q48206860 | Increased neuronal metabolic activity and estrogen receptors in the vertical limb of the diagonal band of Broca in Alzheimer's disease: relation to sex and aging |
| Q46833795 | Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. |
| Q37092283 | Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease |
| Q41652286 | Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China |
| Q77684324 | Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide |
| Q48548934 | Kinetics of muscarinic reduction of IsAHP in hippocampal neurons: effects of acetylcholinesterase inhibitors. |
| Q36044934 | Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease |
| Q30473882 | Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice |
| Q42515808 | Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease |
| Q42494887 | Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease |
| Q48336501 | Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. |
| Q90390163 | M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera |
| Q57445890 | Making drug discovery a SN(i)P |
| Q35483725 | Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve |
| Q44251907 | Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. |
| Q55506979 | Molecular Mechanisms in Alzheimer's Disease. |
| Q36330352 | Molecular neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of oxidative stress |
| Q49831229 | Molecular subtypes of Alzheimer's disease. |
| Q51990804 | Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. |
| Q53215966 | NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. |
| Q91938288 | Nerve Growth Factor Pathobiology During the Progression of Alzheimer's Disease |
| Q39355193 | Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease |
| Q42460969 | Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. |
| Q48275764 | Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation |
| Q34976296 | Neuroplasticity in Alzheimer's disease |
| Q98614937 | Neuropsychiatric Effects of Tamoxifen: Challenges and Opportunities |
| Q34953672 | Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. |
| Q35814369 | Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response |
| Q37794466 | Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease |
| Q33694502 | Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. |
| Q48635466 | Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. |
| Q47830482 | No association between apolipoprotein E alleles and olivopontocerebellar atrophy. |
| Q53235325 | No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. |
| Q35678134 | Novel image-novel location object recognition task sensitive to age-related cognitive decline in nondemented elderly |
| Q37012066 | Novel strategies for Alzheimer's disease treatment |
| Q48110773 | Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype |
| Q53226400 | Peering inside Alzheimer's brains. |
| Q34327769 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease |
| Q37031522 | Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease |
| Q34453112 | Pharmacogenetic screening and therapeutic drugs |
| Q34574406 | Pharmacogenetics in affective disorders |
| Q35983449 | Pharmacogenetics in health-care practice |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q35956177 | Pharmacogenetics-based new therapeutic concepts |
| Q34368342 | Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy |
| Q34273202 | Pharmacogenetics: potential for individualized drug therapy through genetics |
| Q36703598 | Pharmacogenomics and nutrigenomics: synergies and differences |
| Q44163441 | Pharmacogenomics and personalised medicine. SMI Conference on Pharmacogenomics and Personalised Medicine, 26-28 September, 2001, The Hatton, London, UK. |
| Q53247921 | Pharmacogenomics and pharmacogenetics of neurodegenerative diseases: towards new targets. |
| Q36273420 | Pharmacogenomics and therapeutic prospects in Alzheimer's disease |
| Q37111344 | Pharmacogenomics and therapeutic prospects in dementia |
| Q37967607 | Pharmacogenomics in neurology: current state and future steps |
| Q34134861 | Pharmacogenomics of psychiatric disorders |
| Q35142052 | Pharmacogenomics of psychiatric drug treatment |
| Q34286010 | Pharmacogenomics: implications for laboratory medicine |
| Q34952587 | Pharmacogenomics: the future of drug therapy. |
| Q33910630 | Pharmacogenomics: the genomics of drug response |
| Q42355578 | Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications |
| Q42528671 | Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele |
| Q34660846 | Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers |
| Q35486605 | Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease |
| Q51982611 | Protective effect of Rosa laevigata against amyloid beta peptide-induced oxidative stress. |
| Q34667425 | Proteomic identification of biomarkers of vascular injury. |
| Q42940139 | Psychopharmacogenetics and psychiatric genetics: similar methodological challenges. |
| Q35540380 | Reactivation of atrophic neurons in Alzheimer's disease |
| Q41150751 | Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions |
| Q53225915 | Recent advances in the genetics of Alzheimer's disease. |
| Q43841496 | Recent developments in Alzheimer's disease |
| Q34976865 | Receptor pharmacogenetics: relevance to CNS syndromes |
| Q48488509 | Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. |
| Q36212135 | Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease |
| Q73046888 | Regression to the truth: replication of association in pharmacogenetic studies |
| Q28576772 | Regulation of the high-affinity choline transporter activity and trafficking by its association with cholesterol-rich lipid rafts |
| Q53241326 | Relation of apolipoprotein E polymorphism to clinically diagnosed Alzheimer's disease in the Korean population. |
| Q48581083 | Retinal Muller glia secrete apolipoproteins E and J which are efficiently assembled into lipoprotein particles. |
| Q57176186 | Review: Revisiting the human cholinergic nucleus of the diagonal band of Broca |
| Q38495339 | Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. |
| Q34055011 | Role of vascular risk factors and vascular dysfunction in Alzheimer's disease |
| Q34398127 | SNP analysis to dissect human traits. |
| Q73346226 | Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms |
| Q33805200 | Science, medicine, and the future: Postgenomic technologies: hunting the genes for common disorders |
| Q53397893 | Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement. |
| Q34058281 | Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? |
| Q34081504 | Single nucleotide polymorphisms and the future of genetic epidemiology |
| Q48931984 | Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon4 allele on regional cerebral blood flow. |
| Q47887017 | Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study |
| Q48963855 | Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. |
| Q37309743 | Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women |
| Q48536705 | Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease. |
| Q53331582 | The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. |
| Q41235553 | The Alzheimer diseases |
| Q57602052 | The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β |
| Q38559820 | The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease |
| Q54976997 | The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats. |
| Q58777363 | The Role of Magnetoencephalography in the Early Stages of Alzheimer's Disease |
| Q35950342 | The Use of SNPs in Pharmacogenomics Studies. |
| Q24539024 | The apolipoprotein E gene, attention, and brain function |
| Q53234222 | The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. |
| Q33961288 | The cholinergic neuronal phenotype in Alzheimer's disease |
| Q40861115 | The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems |
| Q33624389 | The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging |
| Q42470424 | The effects of apolipoprotein E deficiency on brain cholinergic neurons |
| Q89544479 | The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease |
| Q34741545 | The genetic basis of variability in drug responses |
| Q38558148 | The genetics of dementia in late life |
| Q40873189 | The impact of pharmacogenetics on the future of healthcare |
| Q48528814 | The influence of apolipoprotein E Epsilon4 polymorphism on qEEG profiles in healthy young females: a resting EEG study. |
| Q34116506 | The interface between pharmacoepidemiology and pharmacogenetics |
| Q42560979 | The perils of Alzheimer's drug development |
| Q35039858 | The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia |
| Q33858831 | The potential applications of Apolipoprotein E in personalized medicine |
| Q33950398 | The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models |
| Q35096114 | The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol |
| Q34204390 | The status of ongoing trials for mild cognitive impairment |
| Q33913441 | The use of single-nucleotide polymorphism maps in pharmacogenomics |
| Q54981021 | Translational Bioinformatics: At the Interface of Genomics and Quantitative Genetics |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
| Q33950366 | Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. |
| Q52532967 | [Treatment of Alzheimer' disease: critical evaluation of the use of anticholinesterase] |
| Q44225451 | alpha- and beta-secretase: profound changes in Alzheimer's disease. |
Search more.